Agilent is in a powerful, sustained uptrend, with the stock up 22.59% over the past year and 25.39% year-to-date, and the current price of $172.97 sits at roughly 93.4% of its 52-week range of $108.35 to $177.47. That positioning near the top of the range signals strong momentum rather than a value opportunity, though it also means the stock is extended and vulnerable to profit-taking; the maximum drawdown of -29.87% over the trailing period underscores that this has not been a smooth ride. The stock is trading just below its 52-week high of $177.47, a level that now acts as the key near-term resistance. Short-term momentum is decisively positive and accelerating: the stock is up 12.54% over the past month and 31.58% over three months, far outpacing the S&P 500's 1.22% and 2.69% respective gains, producing relative strength readings of +11.32 and +28.89. The 6-month gain of 41.93% versus the index's 7.48% confirms a persistent, broad-based outperformance rather than a single spike, and the recent sequence of higher lows from the September pullback to $143.12 into the October high of $175.55 shows buyers stepping in on dips. The most recent session's -1.47% pullback from $175.55 to $172.97 is a minor pause within the trend, not a reversal signal, though it bears watching given the extended run. Key support sits at the 52-week low area of $108.35, with intermediate support around the $143-$150 zone that contained the September consolidation; resistance is the $177.47 52-week high, and a clean breakout above that level would confirm the uptrend and likely invite momentum buyers, while a breakdown below $143 would signal a trend change. With a beta of 1.208, the stock is about 21% more volatile than the market, meaning position sizing should account for amplified moves in both directions; the short ratio of 2.09 indicates modest short interest and limited squeeze potential.

Revenue is growing at a healthy and accelerating pace: the most recent quarter (ended July 31, 2026) delivered $1.878 billion in revenue, up 8.06% year-over-year, and the sequential progression from $1.798 billion in Q1 to $1.835 billion in Q2 to $1.878 billion in Q3 shows steady, compounding growth. The segment mix supports this trajectory, with Agilent CrossLab at $786 million, Life Sciences and Applied Markets at $746 million, and Applied Markets at $346 million, meaning the recurring consumables and services business is the largest contributor and provides a durable base. The 8.06% growth rate, combined with the raised full-year profit forecast reported in May 2026, implies the investment case is shifting from a cyclical recovery story to a structural growth-and-margin story, though the pace remains moderate relative to high-growth medtech peers. Profitability is robust and improving: Q3 net income was $362 million on a 19.28% net margin, gross margin was 55.48%, and operating margin reached 23.64%, all marking expansion from the year-ago quarter's 19.33% net margin and 52.59% gross margin. The gross margin has climbed steadily from 52.61% in Q1 to 54.99% in Q2 to 55.48% in Q3, a clear upward trajectory that reflects favorable mix and operating leverage, while the 21.29% operating margin and 25.19% EBITDA margin are solid for the diagnostics and research tools industry. The balance sheet and cash flow profile are strong: debt-to-equity is a conservative 0.50, the current ratio is 1.96, and trailing free cash flow is $1.436 billion, with Q3 free cash flow of $439 million on operating cash flow of $519 million. ROE of 19.33% and ROA of 8.63% confirm efficient capital deployment, and the company returned capital via $72 million in dividends and $78 million in buybacks in the quarter while also deploying $950 million on acquisitions, demonstrating the internal cash generation to fund growth without heavy external financing.